Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

NCT02974153 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1121

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine Disorders

Interventions

BIOLOGICAL: ALD403 (Eptinezumab)
BIOLOGICAL: Placebo

Sponsor

Alder Biopharmaceuticals, Inc.